The US Food and Drug Administration should take a more welcoming view on the use of observational studies to support new efficacy claims for approved drugs, the pharmaceutical industry believes.
Concerns about bias and the lack of randomization in observational studies need not derail the use of such real-world evidence to support efficacy claims but, rather, can be addressed through...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?